Sanguine Biosciences Announces $10 Million Credit Financing from Catalio Capital Management to Fund Continued Growth

2023-10-31

Capital infusion fast-tracks the development of apheresis-derived products critical to cell and gene therapy research and manufacturing. WOBURN, Mass.--(BUSINESS WIRE)-- Sanguine Bio, a leading biospecimen procurement services company that empowers patients to accelerate precision medicine and cell and gene therapy research and development, today announced that it secured $10 million in credit financing from Catalio Capital Management, a leading multi-strategy healthcare and life science investment firm. The loan is from Catalio’s Structured Opportunities Fund, which provides creative and flexible structured capital solutions to healthcare and life sciences companies. The senior secured term loan provides Sanguine with an initial draw of $6 million at close, with an additional $4 million available at the company’s option. Sanguine will use the funds to support its recently launched apheresis donation center, develop instrumental cell & gene therapy products derived from apheresis, including GMP-grade and CD34+ mobilized leukopaks, and fund commercial growth. Catalio Capital Management General Partner and Head of Credit John Henry Iucker, CFA, joins Sanguine’s board of directors as an Observer. “Catalio is thrilled to partner with Sanguine to support its mission of empowering patients to participate in medical research and advance precision medicine,” Mr. Iucker said. “By providing a diversity of annotated and relevant biospecimens essential for clinical research, Sanguine is well-positioned to thrive in the rapidly expanding cell and gene therapy market.” “Our partnership with Catalio is an important step forward for Sanguine as we bridge the gap between researchers and patients, leading to advanced therapies and likely better outcomes,” said Sanguine CEO Brian Neman, MHA. “This financing will enable our business to continue to innovate, grow, and align with our customers’ needs.” About Catalio Capital Management Catalio Capital Management, LP, is a multi-strategy healthcare and life sciences investment firm focusing on breakthrough companies developing the next generation of drugs, devices, diagnostics, and data-driven insights. Catalio's Partnership includes over 44 world-renowned scientists with extensive academic and scientific achievements who have each started well-established companies based on their research. Catalio has offices in New York and London. Learn more about Catalio Capital Management by visiting . About Sanguine Biosciences Sanguine Biosciences is accelerating personalized medicine research by empowering patients with their healthcare data and facilitating participation in biomedical research. Bridging the gap between patients and researchers means securely and efficiently collecting, processing, and delivering patient biospecimens and relevant health data to scientists working on innovative therapies. Sanguine has supported translational and clinical research at 30 of the top 40 global pharmaceutical and biotechnology companies, shortening timelines and validating early-stage results to increase confidence and refine biomarkers in human trials. For the past four years, Sanguine has received the prestigious designation as a “Great Places to Work” company. In 2023, Sanguine was designated on the Inc. 5000 America’s Fastest Growing Private Companies list, Fortune Best Workplaces in BioPharma, and Fortune Best Small Workplaces. Popular media outlets featuring Sanguine include the Fox News Channel, The Washington Post, The Boston Globe, Inc., and many others.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构